Selection of First-Line Therapy for Advanced Follicular Lymphoma
Mené sur 534 patients atteints d'un lymphome folliculaire de stade avancé, cet essai italien compare, du point de vue du délai avant l'échec du traitement, trois protocoles de chimiothérapie en combinaison avec le rituximab
Few topics in the field of hematology/oncology have generated as much controversy and debate in the last 40 years as the proper management of patients with follicular non-Hodgkin lymphoma (FL). Most patients with this disease live in good health for many years after diagnosis whether or not they are treated immediately. A wide spectrum of therapeutic regimens readily induces remissions in FL, but most patients eventually relapse regardless of the initial treatment approach, which leads many physicians to consider the disease incurable with standard treatment. In addition, there is no compelling evidence that initiation of therapy at the time of diagnosis yields improved outcomes in asymptomatic patients with FL; hence “watchful waiting” has become a standard management strategy (which will not be addressed further in this editorial)...
Journal of Clinical Oncology , éditorial en libre accès, 2013